Purple Biotech Initiates Phase 2 Study for NT219 in Head and Neck Cancer

An update from Purple Biotech ( (PPBT) ) is now available.

On June 17, 2025, Purple Biotech announced the initiation of a Phase 2 clinical study for NT219, a novel small molecule targeting oncogenic pathways, in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. This study, conducted in collaboration with the University of Colorado Anschutz Medical Campus, aims to evaluate NT219 in combination with standard treatments pembrolizumab or cetuximab. The study’s initiation marks a significant milestone in Purple Biotech’s efforts to develop therapies that address tumor resistance and improve patient outcomes in a market projected to reach $5 billion by 2030.

The most recent analyst rating on (PPBT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.

Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Their oncology pipeline includes products like CM24, NT219, and CAPTN-3, which target various cancer mechanisms and pathways. The company is headquartered in Rehovot, Israel.

Average Trading Volume: 105,654

Technical Sentiment Signal: Sell

Current Market Cap: $7.05M

See more insights into PPBT stock on TipRanks’ Stock Analysis page.